QuickView for sb 203580 (compound)

1. Monocyte-derived dendritic cells treated with MEK inhibitor U0126 or p38/MAPK inhibitor SB203580
2. Acute monocytic leukemia (AML) THP-1 cells HIV gp120 or LPS stimulated following SB203580 treatment
3. Colon cancer SW480 cells expressing BOP1, CSK2 or NFIL3 treated with different kinase inhibitors
4. Burkitt lymphoma BL-2 cells and tonsil B cells with kinase/enzyme inhibitor treatments
5. Embryonic and induced pluripotent stem cells maintained in naive or primed states

1. p38 MAPK inhibitor SB203580 enhances anticancer activity of PARP inhibitor olaparib in a synergistic…
2. SB203580 protects against inflammatory response and lung injury in a mouse model of lipopolysacchari…
3. SB203580, a p38MAPK inhibitor, attenuates olfactory dysfunction by inhibiting OSN apoptosis in AR mi…
4. The p38 MAPK inhibitor, SB203580, inhibits cell invasion by Neospora caninum.
5. Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors.

There were no clinical trials for sb 203580